Caroline Palomeque
Stock Analyst at Ladenburg Thalmann & Co.
(0.09)
# 4,624
Out of 4,670 analysts
174
Total ratings
31.3%
Success rate
-11.3%
Average return
Main Sectors:
Stocks Rated by Caroline Palomeque
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATHE Alterity Therapeutics | Initiated Coverage: Buy | $10 | $4.67 | +114.13% | 1 | Jun 16, 2026 | |
| ARDX Ardelyx | Initiated Coverage: Buy | $16 | $3.89 | +311.31% | 1 | Jun 16, 2026 | |
| KRYS Krystal Biotech | Initiated Coverage: Buy | $154 | $346.58 | n/a | 2 | Oct 25, 2023 | |
| HRMY Harmony Biosciences Holdings | Initiated Coverage: Buy | $59 → $54 | $38.15 | n/a | 2 | Oct 25, 2023 | |
| HALO Halozyme Therapeutics | Maintained: Buy | $58 | $108.17 | n/a | 7 | Sep 11, 2023 | |
| ASND Ascendis Pharma | Maintained: Buy | $166 | $253.29 | n/a | 12 | Sep 7, 2023 | |
| CMPS COMPASS Pathways | Maintained: Buy | $33 | $13.33 | n/a | 7 | Aug 16, 2023 | |
| ATAI AtaiBeckley | Reiterated: Buy | $11 | $7.38 | n/a | 6 | Aug 11, 2023 | |
| AVXL Anavex Life Sciences | Maintained: Buy | $40 | $3.24 | n/a | 24 | Aug 9, 2023 | |
| DNLI Denali Therapeutics | Reiterated: Buy | $54 | $24.92 | n/a | 14 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 | $11.08 | n/a | 7 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $61 | $10.72 | n/a | 12 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $19.83 | n/a | 2 | Apr 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $5 | $3.57 | n/a | 5 | Apr 23, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $3 | $0.8199 | n/a | 8 | Apr 4, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $0.244 | n/a | 14 | Apr 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $3.95 | n/a | 4 | Apr 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 | $1.06 | n/a | 13 | Mar 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $4 → $40 | $1.52 | n/a | 11 | Mar 20, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | 1,320p | 526p | n/a | 2 | Mar 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $34 | $0.3182 | n/a | 3 | Mar 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $20 | $10.38 | n/a | 5 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $9 | $2.06 | n/a | 6 | Mar 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $8 | $9.55 | n/a | 1 | Aug 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $0.00001 | n/a | 1 | Jun 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $0.001 | n/a | 1 | Jun 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $2.66 | n/a | 1 | May 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $0.075 | n/a | 1 | Apr 24, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $18 | $0.001 | n/a | 1 | Mar 2, 2016 |
Alterity Therapeutics
Jun 16, 2026
Initiated Coverage: Buy
Price Target: $10
Current: $4.67
Upside: +114.13%
Ardelyx
Jun 16, 2026
Initiated Coverage: Buy
Price Target: $16
Current: $3.89
Upside: +311.31%
Krystal Biotech
Oct 25, 2023
Initiated Coverage: Buy
Price Target: $154
Current: $346.58
Upside: n/a
Harmony Biosciences Holdings
Oct 25, 2023
Initiated Coverage: Buy
Price Target: $59 → $54
Current: $38.15
Upside: n/a
Halozyme Therapeutics
Sep 11, 2023
Maintained: Buy
Price Target: $58
Current: $108.17
Upside: n/a
Ascendis Pharma
Sep 7, 2023
Maintained: Buy
Price Target: $166
Current: $253.29
Upside: n/a
COMPASS Pathways
Aug 16, 2023
Maintained: Buy
Price Target: $33
Current: $13.33
Upside: n/a
AtaiBeckley
Aug 11, 2023
Reiterated: Buy
Price Target: $11
Current: $7.38
Upside: n/a
Anavex Life Sciences
Aug 9, 2023
Maintained: Buy
Price Target: $40
Current: $3.24
Upside: n/a
Denali Therapeutics
Aug 9, 2023
Reiterated: Buy
Price Target: $54
Current: $24.92
Upside: n/a
Aug 8, 2023
Maintained: Buy
Price Target: $15
Current: $11.08
Upside: n/a
Aug 3, 2023
Maintained: Buy
Price Target: $61
Current: $10.72
Upside: n/a
Apr 29, 2019
Maintained: Buy
Price Target: $10
Current: $19.83
Upside: n/a
Apr 23, 2019
Rated: Buy
Price Target: $5
Current: $3.57
Upside: n/a
Apr 4, 2019
Maintained: Buy
Price Target: $3
Current: $0.8199
Upside: n/a
Apr 1, 2019
Maintained: Buy
Price Target: $6
Current: $0.244
Upside: n/a
Apr 1, 2019
Downgraded: Hold
Price Target: n/a
Current: $3.95
Upside: n/a
Mar 28, 2019
Maintained: Buy
Price Target: $9
Current: $1.06
Upside: n/a
Mar 20, 2019
Rated: Buy
Price Target: $4 → $40
Current: $1.52
Upside: n/a
Mar 14, 2019
Maintained: Buy
Price Target: 1,320p
Current: 526p
Upside: n/a
Mar 20, 2018
Rated: Buy
Price Target: $34
Current: $0.3182
Upside: n/a
Mar 13, 2018
Rated: Buy
Price Target: $20
Current: $10.38
Upside: n/a
Mar 9, 2018
Rated: Buy
Price Target: $9
Current: $2.06
Upside: n/a
Aug 8, 2017
Rated: Buy
Price Target: $8
Current: $9.55
Upside: n/a
Jun 13, 2017
Rated: Buy
Price Target: n/a
Current: $0.00001
Upside: n/a
Jun 7, 2017
Rated: Buy
Price Target: n/a
Current: $0.001
Upside: n/a
May 17, 2017
Rated: Buy
Price Target: n/a
Current: $2.66
Upside: n/a
Apr 24, 2017
Rated: Buy
Price Target: n/a
Current: $0.075
Upside: n/a
Mar 2, 2016
Initiated Coverage: Buy
Price Target: $18
Current: $0.001
Upside: n/a